Guardion Health Sciences Announces Submission of Patent Application for Treatment of Certain Underlying Conditions Related to Eye Disease

Stock Information for Guardion Health Sciences Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Guardion Health Sciences Inc.

Guardion Health Sciences Announces Financial Results for the Year Ended December 31, 2023
Guardion Health Sciences Announces Entry into Definitive Agreement to Sell its Well-Known Viactiv® Brand and Business to Doctor's Best Inc.
Guardion Health Sciences Announces Financial Results for the Three Months and Nine Months Ended September 30, 2023
Guardion Health Sciences Announces Financial Results for the Three Months and Six Months Ended June 30, 2023
Guardion Health Sciences Announces Appointment of Former Neutrogena and Coca-Cola Executive Jan Hall as President and Chief Executive Officer
Guardion Health Sciences Announces Financial Results for the Quarter Ended March 31, 2023
Guardion Health Sciences Announces Financial Results for the Year Ended December 31, 2022
Guardion Health Sciences Hires Alantra, LLC as its Financial Advisor to Explore Strategic Alternatives to Maximize Stockholder Value

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.